Literature DB >> 15183239

Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital.

R Jung1, D N Fish, M D Obritsch, R MacLaren.   

Abstract

Antimicrobial resistance in Pseudomonas aeruginosa is a serious clinical problem. To determine the incidence of multi-drug resistant P. aeruginosa, resistance rates of P. aeruginosa clinical isolates against commonly used antibiotics were evaluated for the period 1998 to 2002. Multi-drug resistance was defined as resistance to at least three of the four drugs, ceftazidime, imipenem, ciprofloxacin, and tobramycin. Resistance to most anti-pseudomonal agents has increased by >20% over the five-year period, with dramatic increases observed with fluoroquinolones, tobramycin, and imipenem (resistance increased by 34-37%). In 1998, 78% of isolates were susceptible to all four anti-pseudomonal agents and no isolate was considered multi-drug resistant. However, in 2002, only 27% of isolates were sensitive to all four of the drugs and 32% were considered multi-drug resistant. Multi-drug resistance in individual institutions may be significantly higher than rates reported in nationwide surveillance studies and may more accurately reflect the true magnitude of local resistance problems. On-going surveillance within individual institutions is critical for the selection of appropriate empiric antimicrobial therapy. Copyright 2004 The Hospital Infection Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183239     DOI: 10.1016/j.jhin.2004.03.001

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  7 in total

1.  Glutathione-Disrupted Biofilms of Clinical Pseudomonas aeruginosa Strains Exhibit an Enhanced Antibiotic Effect and a Novel Biofilm Transcriptome.

Authors:  William Klare; Theerthankar Das; Amaye Ibugo; Edwina Buckle; Mike Manefield; Jim Manos
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

2.  The relative contribution of efflux and target gene mutations to fluoroquinolone resistance in recent clinical isolates of Pseudomonas aeruginosa.

Authors:  S A Dunham; C J McPherson; A A Miller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-01-23       Impact factor: 3.267

3.  Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients.

Authors:  Antonella Agodi; Martina Barchitta; Rosalba Cipresso; Loredana Giaquinta; Maria Antonietta Romeo; Carmelo Denaro
Journal:  Intensive Care Med       Date:  2007-05-15       Impact factor: 17.440

4.  Prevalence of multiple antibiotics resistant (MAR) Pseudomonas species in the final effluents of three municipal wastewater treatment facilities in South Africa.

Authors:  Emmanuel E Odjadjare; Etinosa O Igbinosa; Raphael Mordi; Bright Igere; Clara L Igeleke; Anthony I Okoh
Journal:  Int J Environ Res Public Health       Date:  2012-06-01       Impact factor: 3.390

5.  Class 1 integron and Imipenem Resistance in Clinical Isolates of Pseudomonas aeruginosa: Prevalence and Antibiotic Susceptibility.

Authors:  S Yousefi; Mr Nahaei; S Farajnia; M Ghojazadeh; Mt Akhi; Y Sharifi; M Milani; R Ghotaslou
Journal:  Iran J Microbiol       Date:  2010-09

6.  Isolation of Pseudomonas aeruginosa strains from dental office environments and units in Barretos, state of São Paulo, Brazil, and analysis of their susceptibility to antimicrobial drugs.

Authors:  Ana Claudia de Oliveira; Renato Pariz Maluta; Ariel Eurides Stella; Everlon Cid Rigobelo; José Moacir Marin; Fernando Antonio de Ávila
Journal:  Braz J Microbiol       Date:  2008-09-01       Impact factor: 2.476

7.  Prevalence of β-lactamase genes, class 1 integrons, major virulence factors and clonal relationships of multidrug-resistant Pseudomonas aeruginosa isolated from hospitalized patients in southeast of Iran.

Authors:  Hosein Sharifi; Gholamreza Pouladfar; Mohammad Reza Shakibaie; Bahman Pourabbas; Jalal Mardaneh; Shahla Mansouri
Journal:  Iran J Basic Med Sci       Date:  2019-07       Impact factor: 2.699

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.